Conditions: Lung Cancer, Nonsmall Cell; Thyroid Cancer; Solid Tumor
Intervention: Drug: BLU-667
Sponsor: Blueprint Medicines Corporation
Not yet recruiting - verified January 2017
http://ift.tt/2kmTky3
http://ift.tt/2kcrkLc
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
http://ift.tt/2kHpz8A http://ift.tt/2kN9PAc
-
Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Purpose:Cancer cells often have deficiencie...
-
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com, Molec...
-
Abstract Objectives Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ...
-
EPSIN 3, a novel p53 target, regulates the apoptotic pathway and gastric carcinogenesis via Neoplasia Publication date: March 20...
-
Author: Stachon, Peter MD *; Heidenreich, Adrian MS *; Merz, Julian MSc; Hilgendorf, Ingo MD; Wolf, Dennis MD; Willecke, Florian MD; von Ga...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου